Autologous Dendritic Cell Vaccine in Patients With Soft Tissue Sarcoma

Summary

The purpose of this study is to achieving a six-month progression free survival (PFS) of patients receiving autologous dendritic cell vaccine (ADKV) loaded with allogeneic tumor lysate expression of cancer-testis antigens (CTA) in patients with soft tissue sarcomas

Timeline

Start

2013-06

Primary completion

2020-09

Completion

2020-09

Drugs

Indications